Investment
Features
FeesSafety
Academy
More
Pluang+

Compare KB Financial Group, Inc. (KB) vs BIO-TECHNE Corp (TECH) Price & Performance

KB Financial Group, Inc.Trade
BIO-TECHNE CorpTrade

Price performance (Past 24H)

Key statistics

KB Financial Group, Inc. vs BIO-TECHNE Corp — how do they compare? KB Financial Group, Inc. trades at $117.44 (market cap $42.79B), while BIO-TECHNE Corp trades at $72.12 (market cap $11.24B). The key difference: KB Financial Group, Inc. is far larger — about 3.8× BIO-TECHNE Corp's market cap, and KB Financial Group, Inc. pays the higher dividend (2.6%). Which is the better fit depends on your goals.

KBTECH
Market Cap
$42.79B$11.24B
Sector
FinancialsHealth
52-Week High
$124.01$72.29
52-Week Low
$77.50$43.31
Dividend Yield
2.6%0.44%
Enterprise Value
$11.32B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

KB Financial Group, Inc.

KB Financial Group (KB) trades at $124.01, up 2.22% today, with a bullish technical outlook from moving averages and recent momentum. The stock shows strong fundamentals, with net income margin at 27.82% and a P/E ratio of 11.03, indicating potential undervaluation. Recent earnings beats in Q1 and Q2 2026, alongside positive news coverage on diversification efforts, support investor confidence.

The outlook for KB is positive, driven by earnings growth and strategic expansion into non-banking segments. Risks include volatile cash flow trends and high interest expenses. Analyst consensus is mixed but leans hold, with institutional interest steady. Upside potential exists if profitability trends continue, though macroeconomic factors could pressure performance.

BIO-TECHNE Corp

Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.

Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.

Returns comparison

Trailing returns across standard periods

About KB Financial Group, Inc.

KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.

Read more on KB

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Read more on TECH